Panntherapi is part of the 51 selected tech companies (7 biotechs) out of 551 full proposals submitted, and will received a grant of 2.5M€ ti pursue the dévelopement of the PTI5803 product in epilepsy and equity up to 9.8M€ in a next funding round with a lead investor.